PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer - Cancer Therapy Advisor

PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer  Cancer Therapy Advisor

Olaparib plus temozolomide appeared safe and active in relapsed small cell lung cancer, according to the results of a single-arm phase 1/2 trial.



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development